title: Type 1 diabetes promotes disruption of advanced atherosclerotic lesions in LDL receptor-deficient mice.
abstract: Cardiovascular disease, largely because of disruption of atherosclerotic lesions, accounts for the majority of deaths in people with type 1 diabetes. Recent mouse models have provided insights into the accelerated atherosclerotic lesion initiation in diabetes, but it is unknown whether diabetes directly worsens more clinically relevant advanced lesions. We therefore used an LDL receptor-deficient mouse model, in which type 1 diabetes can be induced at will, to investigate the effects of diabetes on preexisting lesions. Advanced lesions were induced by feeding mice a high-fat diet for 16 weeks before induction of diabetes. Diabetes, independently of lesion size, increased intraplaque hemorrhage and plaque disruption in the brachiocephalic artery of mice fed low-fat or high-fat diets for an additional 14 weeks. Hyperglycemia was not sufficient to induce plaque disruption. Furthermore, diabetes resulted in increased accumulation of monocytic cells positive for S100A9, a proinflammatory biomarker for cardiovascular events, and for a macrophage marker protein, without increasing lesion macrophage content. S100A9 immunoreactivity correlated with intraplaque hemorrhage. Aggressive lowering primarily of triglyceride-rich lipoproteins prevented both plaque disruption and the increased S100A9 in diabetic atherosclerotic lesions. Conversely, oleate promoted macrophage differentiation into an S100A9-positive population in vitro, thereby mimicking the effects of diabetes. Thus, diabetes increases plaque disruption, independently of effects on plaque initiation, through a mechanism that requires triglyceride-rich lipoproteins and is associated with an increased accumulation of S100A9-positive monocytic cells. These findings indicate an important link between diabetes, plaque disruption, and the innate immune system.
authors.affiliation: Department of Pathology, University of Washington, Seattle, WA 98195, USA.
authors.forename: Fredrik
authors.initials: F
authors.lastname: Johansson
authors.forename: Farah
authors.initials: F
authors.lastname: Kramer
authors.forename: Shelley
authors.initials: S
authors.lastname: Barnhart
authors.forename: Jenny E
authors.initials: JE
authors.lastname: Kanter
authors.forename: Tomas
authors.initials: T
authors.lastname: Vaisar
authors.forename: Rachel D
authors.initials: RD
authors.lastname: Merrill
authors.forename: Linda
authors.initials: L
authors.lastname: Geng
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Oka
authors.forename: Lawrence
authors.initials: L
authors.lastname: Chan
authors.forename: Alan
authors.initials: A
authors.lastname: Chait
authors.forename: Jay W
authors.initials: JW
authors.lastname: Heinecke
authors.forename: Karin E
authors.initials: KE
authors.lastname: Bornfeldt
mesh_terms: D000818:Animals; D050197:Atherosclerosis / Q000473:pathology*; D040502:Calgranulin B / Q000378:metabolism; D003922:Diabetes Mellitus, Type 1 / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D004041:Dietary Fats / Q000008:administration & dosage; D005260:Female; D008264:Macrophages / Q000378:metabolism; D051379:Mice; D018345:Mice, Knockout; D011973:Receptors, LDL / Q000235:genetics / Q000502:physiology*
chemical_list: D040502:Calgranulin B; D004041:Dietary Fats; D011973:Receptors, LDL